Dr Reddy receives Zytorvi approval: Citi targets Dr Reddy stock at USD 1,450

Published on 10/21/2026 at 09:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zytorvi cut progression risk 42 percent in a Phase 3 trial. Dr Reddy stock stood at INR 1,235.90 versus its INR 1,414.90 high.

Zytorvi and valuation milestones

Dr Reddy received Zytorvi approval for esophageal cancer on October 21, 2026.
Citi raised its target from USD 1,040 to USD 1,450 on September 29, 2026.
Dr Reddy's market capitalization was INR 1.0 trillion on October 21, 2026.

Dr Reddy stock, pharmaceuticals, Zytorvi, regulatory approval, NSE, Illustration mit AI erstellt.

Dr Reddy Laboratories received Indian regulatory approval for Zytorvi in advanced esophageal cancer on October 21, 2026, expanding the drug's approved use beyond nasopharyngeal carcinoma. The approval follows Phase 3 data showing a 42 percent reduction in the risk of disease progression or death compared with chemotherapy alone, according to ScanX.

Three dated milestones shape the setup

On September 29, 2026, Citigroup raised its target for Dr. Reddy's Laboratories from USD 1,040 to USD 1,450 and upgraded the stock to Buy, as reported by MarketBeat. On October 7, 2026, the company scheduled its results for the quarter and six months ended September 30, 2026, for October 23, 2026, according to FinancialFilings. The October 21 Zytorvi decision is the latest milestone.

What does Zytorvi add?

The trial reported median overall survival of 17.7 months with Zytorvi and chemotherapy, versus 12.9 months with chemotherapy alone, a 4.8-month difference. The new indication therefore adds a measurable clinical outcome to Dr. Reddy's oncology portfolio, while the October 23 results will provide the next company-wide financial checkpoint.

Earlier earnings set a lower base

In the quarterly results reported on July 23, 2026, Dr. Reddy's posted earnings per share of USD 0.06 versus a USD 0.09 consensus estimate, while revenue was USD 850.26 million against USD 850.56 million expected, according to MarketBeat. The figures make the coming report important for judging whether new products can offset pressure in established businesses.

NSE valuation before results

Dr Reddy stock stood at INR 1,235.90 on India's NSE on October 21, 2026 at 12:30 p.m. IST. The same quote showed a 52-week range of INR 1,101.00 to INR 1,414.90 and a market capitalization of INR 1.0 trillion.

The next dated events are the October 23, 2026 results release and the earnings call scheduled for October 23, 2026 at 7:30 p.m. IST, according to FinancialFilings.